Active Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL)

CD253; TNFSF10; APO2L; Apo2-L; TL2; TRAIL; Tumor Necrosis Factor Ligand Superfamily Member 10; Apo-2 Ligand

ACTIVITY TEST

Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL), encoded by the TNFSF10 gene, is a type II transmembrane protein belonging to the tumor necrosis factor (TNF) superfamily. It primarily functions to induce selective apoptosis in transformed or cancerous cells while sparing most normal cells, making it a promising candidate for antitumor therapy. TRAIL exerts its pro-apoptotic effects by binding to specific death receptors on the cell surface, triggering the extrinsic apoptotic signaling cascade, including caspase activation and subsequent cellular breakdown. Its selective cytotoxicity offers significant advantages over many conventional chemotherapeutic agents, attracting extensive research in oncology and immunotherapy. TRAIL and FAS are both death receptor ligands in the TNF superfamily and can cooperatively activate extrinsic apoptotic pathways.Thus a functional ELISA assay was conducted to detect the interaction of recombinant mouse TRAIL and recombinant mouse FAS. Briefly, TRAIL was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to FAS-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-TRAIL pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37℃, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 µL stop solution to the wells and read at 450/630nm immediately. The binding activity of recombinant mouse TRAIL and recombinant mouse FAS was shown in Figure 1, the EC50 for this effect is 0.0031µg/mL.

USAGE

Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

STORAGE

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

STABILITY

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
PLOS ONE Intranasal Administration of Recombinant TRAIL Down-Regulates CXCL-1/KC in an Ovalbumin-Induced Airway Inflammation Murine Model Pubmed:25506835
PLOS ONE Soluble TRAIL Concentration in Serum Is Elevated in People with Hypercholesterolemia PubMed: 26633016
Scientific Reports Non-alcoholic fatty liver disease, vascular inflammation and insulin resistance are exacerbated by TRAIL deletion in mice pubmed:28507343
Journal of Molecular Medicine TRAIL and TRAIL Receptors as Prognostic Markers in Breast Cancer Patients Pubmed: 31183506
life sciences Nifuroxazide attenuates experimentally-induced hepatic encephalopathy and the associated hyperammonemia and cJNk/caspase-8/TRAIL activation in rats Pubmed: 32259601
Int Immunopharmacol Cardio-protective impact of gabapentin against doxorubicin-induced myocardial toxicity in rats; emphasis on modulation of inflammatory-apoptotic signaling Pubmed: 33199237
ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY Chemo-preventive effect of crocin against experimentally-induced hepatocarcinogenesis via regulation of apoptotic and Nrf2 signaling pathways Pubmed: 32942000
J Biochem Mol Toxicol Tranilast abrogates cisplatin©\induced testicular and epididymal injuries: An insight into its modulatory impact on apoptosis/proliferation 34047436